US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’
Executive Summary
Expert panels may be used to help the FDA decide when and how a new biomarker could be leveraged for regulatory purposes. Participants at workshop on allergy and asthma biomarkers also discuss need for standardization of food allergy trials and new trial design approaches.